Sarepta Therapeutics

Insider buying can be an encouraging signal for potential investors. Insider purchasing was seen at companies favored by Carl Icahn and George Soros last week. The CEO of an industrial giant put his money where his mouth is as well. Conventional wisdom says that insiders and 10% owners really...

This weekend's Barron's cover story looks at why pharmaceutical giants are making big bets on gene therapy. See which companies already have been snapped up and which ones may be the next targets. Other notable articles offer a look at the implications of the tax law and a retirement guide...

This weekend's Barron's takes a look at the unusual value stock picks at one off the radar hedge fund. Other featured articles offer the prospects for top banks now that they have pulled back and a biotech company that is a potential takeover target. The outlook for an auto parts...

Sarepta Therapeutics Inc (NASDAQ: SRPT), a biopharmaceutical company that focuses on the treatment of rare diseases, such as Duchenne Muscular Dystrophy (DMD), has become one of the most debated stocks of 2016. After bottoming at $8 per share in early 2016 the stock soared as high as $63.73...

Sarepta Therapeutics Inc (NASDAQ: SRPT) announced Tuesday that the Patent Trial and Appeal Board issued two favorable decisions for Sarepta which refused BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)'s claims. In a report, Brian Skorney of Baird suggested the PTAB's ruling implies Sarepta...

Sarepta Therapeutics Inc (NASDAQ: SRPT) hosted a conference call Tuesday to discuss its newly approved drug, Exondys 51 (eteplirsen) injection, which happens to be the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Sarepta said Exondys 51 will be available in a...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 20 percent on Thursday after reports surfaced that the U.S. Food and Drug Administration may pressure the company to provide its Duchenne muscular dystrophy patients with at-cost access to its eteplirsen therapy on a "...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) were trading higher by 20 percent at one point early Friday morning on no confirmed news reports. Sarepta's investor relations website showed no new updates. Meanwhile, Twitter users were sharing various theories to explain the unexpected surge in...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 40 percent on Thursday after the U.S. Food and Drug Administration released briefing documents which consisted of an updated clinical review of the company's Duchenne muscular dystrophy drug, eteplirsen. According to The...

Featured stories this weekend in Barron's ponder the prospects for a Detroit automaker, a semiconductor giant and the inventor of Bubble Wrap. This issue also has a look at a jet propulsion company and a pair of small cap banks. Other articles discuss the state of the U.S. auto industry, the top...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) were trading higher by more than 3 percent on Friday, but have lost more than 60 percent after the FDA released a briefing document related to the company's eteplirsen. Related Link: Sarepta Crashes 50% Amid Efficacy Concern Related To Eteplirsen...

The cover story in this weekend's Barron's is a look at the biggest battle in biotechnology. This issue also includes a special report on 16 all-star women advisors and a look at companies that could double earnings. The prospects for Whirlpool, Procter & Gamble, Express...

U.S. stocks continued to charge forward as the Dow closed above the 17,000 mark as consumer confidence rose more than expected in October. The Federal Reserve gathered Tuesday and will release a statement on Wednesday at 2:00 p.m. ET. It is not a foregone conclusion that the Federal Reserve...